Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition and use thereof for treating diseases

A composition and drug technology, applied in the field of microbial pharmacy, can solve the problems that ordinary patients cannot bear, delay the treatment time of patients, and poor treatment effect of patients, and achieve the effect of increasing survival rate, prolonging survival period and inhibiting development

Active Publication Date: 2021-05-14
BEIJING SCITOP BIO TECH CO LTD
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, this type of treatment also has the following problems: slow onset, with a median onset time of 12 weeks, which may delay the patient's treatment time; some patients have poor treatment effect; cause side effects in patients, such as colitis, diarrhea, Immune-related adverse reactions (irAEs) such as dermatitis, hepatitis, and endocrine diseases, which may lead to early termination of treatment; and expensive, making it unaffordable for ordinary patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition and use thereof for treating diseases
  • Pharmaceutical composition and use thereof for treating diseases
  • Pharmaceutical composition and use thereof for treating diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: Oral administration of Lactobacillus rhamnosus Probio-M9 combined with PD-1 immunomodulator for the treatment of digestive tract tumors.

[0060] Materials and methods

[0061] Purchase SPF grade 6-8 week old female Balb / c mice. Adaptive feeding for one week. Mice belonging to the same group housed in different cages were randomly exchanged during the experiment.

[0062] Isotype antibody: Rat IgG2a, Sino-US Crown Biotechnology Co., Ltd., product number: CVP039;

[0063] PD-1 antibody (or aPD-1 for short): RMP1-14, Sino-US Crown Biotechnology Co., Ltd., product number: CVP033;

[0064] Probio-M9: fermented freeze-dried powder; Shenzhen Unknown Jun Biotechnology Co., Ltd.

[0065] Antibiotic treatment: ampicillin (Ampicillin 1mg / ml), neomycin (Neomycin10mg / ml), metronidazole (Metronidazole10mg / ml), vancomycin (Vancomycin5mg / ml) and amphotericin B (AmphotericinB 0.1mg / ml ).

[0066] CT26 cells: colon cancer cells, purchased from Shanghai Institute of Biol...

Embodiment 2

[0087] Example 2: Comparison of Lactobacillus rhamnosus Probio-M9 and a mixed strain containing Lactobacillus rhamnosus Probio-M9 in PD-1 antibody treatment

[0088] Materials and methods

[0089] Probiotic 2: Lactobacillus rhamnosus Probio-M9; Probiotic 4: Lactobacillus casei Zhang; Probiotic 6: Mixed strains: combination of Lactobacillus rhamnosus Probio-M9+Lactobacillus casei Zhang.

[0090] Other materials and methods are the same as in Example 1.

[0091] Table 2. Experimental design of the antitumor effect of the test substance in the mouse colon cancer CT26 model

[0092]

[0093] Table 3. Drug efficacy analysis table of each group in mouse colon cancer CT26 model

[0094]

[0095] Relative tumor proliferation rate, T / C%, that is, at a certain time point, the percentage value of the relative tumor volume or tumor weight between the treatment group and the control group. Calculated as follows:

[0096] T / C%=T RTV / C RTV ×100% (T RTV : mean RTV of the treatme...

Embodiment 3

[0101] Example 3: Lactobacillus rhamnosus Probio-M9 promotes the expression of IL-6 in THP-1 cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Mean tumor volumeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to pharmaceutical compositions and use thereof for treating diseases. A pharmaceutical composition is provided. The pharmaceutical composition comprises an immune signaling pathway modulator and an amount of Lactobacillus rhamnosus in an amount sufficient to enhance a therapeutic response of a subject to the immune signaling pathway modulator. The invention belongs to the field of microbial medicines. The lactobacillus rhamnosus which is preserved in the China General Microbiological Culture Collection Center with the preservation number of CGMCC No.18639 is orally taken, so that the response rate of PD-1 treatment accepted by tumor patients can be improved, the development of tumors is inhibited, and the lifetime is prolonged; the oral treatment mode is simple and noninvasive, and no extra harm is caused to the body of a patient basically; the lactobacillus rhamnosus is resistant to acid and alkali, and can be stably colonized through a gastrointestinal tract environment; and the bacterial powder fermentation freeze-drying process is mature and stable.

Description

technical field [0001] The invention relates to the field of microbial pharmacy, in particular to a pharmaceutical composition containing Lactobacillus rhamnosus and its use for treating cancer. Background technique [0002] Surgery, chemotherapy and radiotherapy are the "troika" of traditional cancer treatment. However, these traditional methods generally have the characteristics of low cure rate, easy recurrence, and large side effects. In recent years, immune checkpoint inhibitors (ICB), represented by PD-1 / PD-L1 inhibitors, have gradually become new stars in cancer treatment. This type of drug can effectively prevent the inhibitory effect of co-inhibitory factors on T cells by blocking the binding of receptors and ligands of immune checkpoint molecules such as PD-1 / PD-L1 and CTLA-4, and promote the further activation of T cells. Proliferation and differentiation, and finally achieve the elimination of tumor cells. [0003] PD-1 (programmed death 1, programmed death re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/747A61K45/06A61P37/04A61P35/00
CPCA61K35/747A61K45/06A61P37/04A61P35/00
Inventor 刘晓军张凌宇其木格苏都
Owner BEIJING SCITOP BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com